Harbour BioMed Public Relations
E-mail: pr@harbourbiomed.com
Harbour BioMed licensed a midphase PD-L1 antibody from Kelun Biotech for development and commercialization outside of Greater China. Kelun stands to earn up to $350 million, but the partners did not specify how much the deal was worth upfront.
Harbour BioMed Public Relations
E-mail: pr@harbourbiomed.com